VBL Therapeutics

[On Demand]
Search General Info
Search Education
Search Partnering Companies
VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.
VBL has pioneered and is actively developing three novel platform technologies.
The Company’s most advanced program is the anti-cancer gene-therapy program, in which VB-111 is the lead candidate. VB-111 is positioned to potentially treat a wide range of solid tumors. VB-111 is conveniently administered as an IV infusion once every 6-8 weeks. It has been observed to be well-tolerated in >300 cancer patients. The mechanism of VB-111 combines blockade of tumor vasculature with an anti-tumor immune response. This mechanism may retain activity regardless of baseline tumor mutations or the identity of the pro-angiogenic factors secreted by the tumor. VBL has launched OVAL, a potential-registration Phase 3 study in Ovarian Cancer.
Ticker:
VBLT
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Israel
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
VB-111
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Chief Executive Officer
Vascular Biogenics Ltd.